Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial ...
ASCO GI 2021: Phase 3 KEYNOTE-177 Trial
Asco 2020 – Keytruda a “new standard” in biomarker-driven cancer | Evaluate
colon Archives - Onco Americas
Pembrolizumab Shows Continued PFS Benefit in MSI-H/dMMR Metastatic Colorectal Cancer
Kaplan-Meier curves for (A) progression-free survival (PFS) and (B) for... | Download Scientific Diagram
Crossing survival curves of KEYNOTE-177 illustrate the rationale behind combining immune checkpoint inhibition with chemotherapy - The Lancet Oncology
Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer | NEJM
Kaplan–Meier survival plots for colorectal cancer according to combined... | Download Scientific Diagram
Quality of Life Improvement Greater with Front-Line Pembrolizumab
Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study - The Lancet Oncology
Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer | NEJM
Immunogenomics of Colorectal Cancer Response to Checkpoint Blockade: Analysis of the KEYNOTE 177 Trial and Validation Cohorts - ScienceDirect
Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study - The Lancet Oncology
OXALIPLATIN/5FU/LV IN STAGE II AND III COLON CANCER: Updated results (as of January 04) for efficacy and neurotoxicity of the MO
Cancers | Free Full-Text | Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma
KEYNOTE-177 - Advanced MSI-H/dMMR Colorectal Cancer (CRC) - HCP
Cancer Trial Results
KEYNOTE-177: New Analysis Confirms Benefit of Pembrolizumab vs Chemotherapy in Microsatellite Instability–High Advanced Colorectal Cancer - The ASCO Post
Cancers | Free Full-Text | Treatments after Immune Checkpoint Inhibitors in Patients with dMMR/MSI Metastatic Colorectal Cancer
ASCO GI 2021: Phase 3 KEYNOTE-177 Trial
Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study - Annals of Oncology
